NT-proBNP has been proven to be a useful biomarker for prognostic evaluation of chronic heart failure patients, but it remains unclear how prognostic evidence can be translated into clinical practice to enhance heart failure management. The Asia Pacific Cardiac Webinar brings together global and regional experts to discuss the practical use of NT-proBNP as a prognostic marker for chronic heart failure management in different clinical settings.

Participants include James L. Januzzi, MD from the United States; Yi-Heng Li, MD, PhD, FACC, FESC from Taiwan; and Prof. Dr. Naoki Sato, MD, PhD, FESC, FJCA, FJCC from Japan. Check out the video below to understand:

• The APAC Experts Consensus’ recommendation on the prognostic thresholds of NT-proBNP to determine which patients are at increased risk of poor outcomes in different clinical settings
• How to incorporate NT-proBNP prognostic information in clinical decisions for better management of heart failure patients